Literature DB >> 23208470

ARID1A mutations in cancer: another epigenetic tumor suppressor?

Jennifer N Wu1, Charles W M Roberts.   

Abstract

UNLABELLED: Although disordered chromatin organization has long been recognized as a feature of cancer, the molecular underpinnings of chromatin structure, epigenetic regulation, and their relationships to transcription are only beginning to be understood. Cancer genome sequencing studies have revealed a novel theme: frequent mutation of epigenetic regulators. Among these, the ARID1A/BAF250A subunit of the SWI/SNF (BRG1-associated factors) chromatin remodeling complex has emerged as recurrently mutated in a broad array of tumor types. We review the genomic and functional data supporting classification of ARID1A as a tumor suppressor. SIGNIFICANCE: Mutations in chromatin remodeling complex genes are increasingly recognized in many cancer types. However, the mechanisms by which chromatin remodeling complexes contribute to gene expression and the cancer phenotype are poorly understood. Understanding how mutation of chromatin remodelers facilitates transformation may offer the potential for development and implementation of novel therapies for cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208470      PMCID: PMC3546152          DOI: 10.1158/2159-8290.CD-12-0361

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  60 in total

Review 1.  Recent advances in understanding chromatin remodeling by Swi/Snf complexes.

Authors:  Joseph A Martens; Fred Winston
Journal:  Curr Opin Genet Dev       Date:  2003-04       Impact factor: 5.578

Review 2.  A continuum model for tumour suppression.

Authors:  Alice H Berger; Alfred G Knudson; Pier Paolo Pandolfi
Journal:  Nature       Date:  2011-08-10       Impact factor: 49.962

3.  Frequent low expression of chromatin remodeling gene ARID1A in breast cancer and its clinical significance.

Authors:  Xianyu Zhang; Youxue Zhang; Yanmei Yang; Ming Niu; Shanshan Sun; Hongfei Ji; Yuyan Ma; Guodong Yao; Yongdong Jiang; Ming Shan; Guoqiang Zhang; Da Pang
Journal:  Cancer Epidemiol       Date:  2011-09-01       Impact factor: 2.984

4.  Dynamics of expression of ARID1A and ARID1B subunits in mouse embryos and in cells during the cell cycle.

Authors:  Angel Flores-Alcantar; Adriana Gonzalez-Sandoval; Diana Escalante-Alcalde; Hilda Lomelí
Journal:  Cell Tissue Res       Date:  2011-06-07       Impact factor: 5.249

Review 5.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

6.  Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas.

Authors:  Kimberly C Wiegand; Anna F Lee; Osama M Al-Agha; Christine Chow; Steve E Kalloger; David W Scott; Christian Steidl; Sam M Wiseman; Randy D Gascoyne; Blake Gilks; David G Huntsman
Journal:  J Pathol       Date:  2011-05-18       Impact factor: 7.996

7.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

Review 8.  Emerging epigenetic targets and therapies in cancer medicine.

Authors:  Relja Popovic; Jonathan D Licht
Journal:  Cancer Discov       Date:  2012-04-23       Impact factor: 39.397

9.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

10.  Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.

Authors:  Siân Jones; Meng Li; D Williams Parsons; Xiaosong Zhang; Jelle Wesseling; Petra Kristel; Marjanka K Schmidt; Sanford Markowitz; Hai Yan; Darell Bigner; Ralph H Hruban; James R Eshleman; Christine A Iacobuzio-Donahue; Michael Goggins; Anirban Maitra; Sami N Malek; Steve Powell; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Hum Mutat       Date:  2011-11-23       Impact factor: 4.878

View more
  169 in total

1.  Binding of human SWI1 ARID domain to DNA without sequence specificity: A molecular dynamics study.

Authors:  Qian Sun; Tao Zhu; Chang-Yu Wang; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-07-31

2.  Claudin-4 expression distinguishes SWI/SNF complex-deficient undifferentiated carcinomas from sarcomas.

Authors:  Inga-Marie Schaefer; Abbas Agaimy; Christopher Dm Fletcher; Jason L Hornick
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

3.  Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival.

Authors:  Yali Zhai; Rork Kuick; Courtney Tipton; Rong Wu; Michael Sessine; Zhong Wang; Suzanne J Baker; Eric R Fearon; Kathleen R Cho
Journal:  J Pathol       Date:  2015-09-15       Impact factor: 7.996

4.  Genomic and proteomic characterization of ARID1A chromatin remodeller in ampullary tumors.

Authors:  Anca Nastase; Jin Yao Teo; Hong Lee Heng; Cedric Chuan Young Ng; Swe Swe Myint; Vikneswari Rajasegaran; Jia Liang Loh; Ser Yee Lee; London Lucien Ooi; Alexander Yaw Fui Chung; Pierce Kah Hoe Chow; Peng Chung Cheow; Wei Keat Wan; Rafy Azhar; Avery Khoo; Sam Xin Xiu; Syed Muhammad Fahmy Alkaff; Ioana Cutcutache; Jing Quan Lim; Choon Kiat Ong; Vlad Herlea; Simona Dima; Dan G Duda; Bin Tean Teh; Irinel Popescu; Tony Kiat Hon Lim
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

5.  PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.

Authors:  Thomas Januario; Xiaofen Ye; Russell Bainer; Bruno Alicke; Tunde Smith; Benjamin Haley; Zora Modrusan; Stephen Gould; Robert L Yauch
Journal:  Proc Natl Acad Sci U S A       Date:  2017-10-30       Impact factor: 11.205

Review 6.  Germline variants in SMARCB1 and other members of the BAF chromatin-remodeling complex across human disease entities: a meta-analysis.

Authors:  Till Holsten; Susanne Bens; Florian Oyen; Karolina Nemes; Martin Hasselblatt; Uwe Kordes; Reiner Siebert; Michael C Frühwald; Reinhard Schneppenheim; Ulrich Schüller
Journal:  Eur J Hum Genet       Date:  2018-04-30       Impact factor: 4.246

7.  Microarray pathway analysis indicated that mitogen-activated protein kinase/extracellular signal-regulated kinase and insulin growth factor 1 signaling pathways were inhibited by small interfering RNA against AT-rich interactive domain 1A in endometrial cancer.

Authors:  Ye Yang; Wei Bao; Zhengyu Sang; Yongbing Yang; Meng Lu; Xiaowei Xi
Journal:  Oncol Lett       Date:  2017-11-24       Impact factor: 2.967

8.  A novel strategy to dissect endogenous gene transcriptional regulation in live cells.

Authors:  Wenqing Yang; Siliang Zhang; Yi Zhang; Xin Huang
Journal:  Biochem Biophys Res Commun       Date:  2017-04-19       Impact factor: 3.575

9.  Genomic Characterization of Non-Small-Cell Lung Cancer in African Americans by Targeted Massively Parallel Sequencing.

Authors:  Luiz H Araujo; Cynthia Timmers; Erica Hlavin Bell; Konstantin Shilo; Philip E Lammers; Weiqiang Zhao; Thanemozhi G Natarajan; Clinton J Miller; Jianying Zhang; Ayse S Yilmaz; Tom Liu; Kevin Coombes; Joseph Amann; David P Carbone
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Inactivating ARID1A Tumor Suppressor Enhances TERT Transcription and Maintains Telomere Length in Cancer Cells.

Authors:  Yohan Suryo Rahmanto; Jin-Gyoung Jung; Ren-Chin Wu; Yusuke Kobayashi; Christopher M Heaphy; Alan K Meeker; Tian-Li Wang; Ie-Ming Shih
Journal:  J Biol Chem       Date:  2016-03-07       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.